Omeros Corporation is a clinical-stage biopharmaceutical company organized around inflammation and disorders of the central nervous system. The firm's product candidates are derived from its proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The company's lead PharmacoSurgery product candidate, OMS103HP, is in Phase III clinical program for evaluating OMS103HPs safety and ability to improve postoperative joint function and reduce pain following arthroscopic anterior cruciate ligament; and to reduce pain and improve postoperative joint function following arthroscopic meniscectomy surgery. Its PharmacoSurgery product candidates also include OMS302, which completed its Phase I/II clinical trial for use during ophthalmological procedures; and OMS201, which is in Phase I/II clinical trial for use during urological surgery. The company also engages in developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPAR?) agonists for the treatment and prevention of addiction to substances of abuse. Its pipeline of preclinical product development programs include MASP-2 program for developing proprietary mannan-binding lectin-associated serine protease-2 antibody therapies to treat disorders caused by complement-activated inflammation; PDE10 program for developing proprietary compounds to treat schizophrenia and other psychotic disorders; PDE7 program for developing proprietary compounds to treat movement disorders; and GPCR program for the de-orphanization of orphan G protein-coupled receptors
